Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 4/2012

01-04-2012 | Editorial

Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C

Authors: Amit G. Singal, Jorge A. Marrero

Published in: Digestive Diseases and Sciences | Issue 4/2012

Login to get access

Excerpt

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and one of the leading causes of death among patients with cirrhosis. Its incidence is expected to continue increasing over the next 20 years and to peak around 2030 [1]. Although hepatitis B remains the most common risk factor worldwide, chronic hepatitis C virus (HCV) infection is the driving force for the increased incidence of HCC in Western countries and Japan [1]. Therefore, strategies aimed at eliminating the virus may provide opportunities for primary and secondary prevention of the development of HCC. …
Literature
1.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.PubMedCrossRef
2.
Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–1055.PubMedCrossRef
3.
Singh RK, Gutman M, Bucana CD, et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 1995;92:4562–4566.PubMedCrossRef
4.
Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 1993;17:389–394.PubMedCrossRef
5.
Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–288, 288 e281.
6.
Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015–1023; Discussion 1947.
7.
Bruix J, Poynard T, Colombo M, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011;140:1990–1999.PubMedCrossRef
8.
Afdhal NH, Levine R, Brown RJ, et al. Colchicine versus peginterferon alfa 2b long-term therapy: results of the 4 year COPILOT trial. In: 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy; 2008.
9.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.PubMedCrossRef
10.
Margarit C, Escartin A, Castells L, et al. Resection for hepatocellular carcinoma is a good option in Child–Turcotte–Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl. 2005;11:1242–1251.PubMedCrossRef
11.
Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–207.PubMedCrossRef
12.
Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851–858.PubMedCrossRef
13.
Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140:840–849; Quiz e812.
14.
Komorizono Y, Sako K, Yamasaki N, et al. Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy. Anticancer Res. 2002;22:3573–3578.PubMed
15.
Kubo S, Nishiguchi S, Hirohashi K, et al. Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res. 2001;92:59–66.PubMedCrossRef
16.
Uenishi T, Kubo S, Hirohashi K, et al. Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2002;24:404–412.PubMedCrossRef
17.
Uenishi T, Nishiguchi S, Tamori A, et al. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2006;36:195–200.PubMedCrossRef
18.
Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755.PubMedCrossRef
19.
McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838.PubMedCrossRef
20.
Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.PubMedCrossRef
21.
Miyatake H, Kobayashi Y, Iwasaki Y, et al. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. doi:10.​1007/​s10620-011-1934-1.
Metadata
Title
Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C
Authors
Amit G. Singal
Jorge A. Marrero
Publication date
01-04-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2069-8

Other articles of this Issue 4/2012

Digestive Diseases and Sciences 4/2012 Go to the issue

Stanford Multidisciplinary Seminars

An Evolving Case of Concurrent Eosinophilic Esophagitis and Eosinophilic Gastroenteritis

Original Article

Ca2+/Calmodulin-Dependent Protein Kinase II Mediates Platelet-Derived Growth Factor-Induced Human Hepatic Stellate Cell Proliferation

Original Article

Presence of Minimal Change Esophagitis Closely Correlates with Pathological Conditions in the Stomach

Original Article

Identification of Suitable Reference Genes for qPCR Analysis of Serum microRNA in Gastric Cancer Patients

Correspondence

Hepatorenal Syndrome: Is It the Magnitude of the Renal Failure that Matters?

Correspondence

Thalidomide Treatment in Cirrhotic Patients with Severe Anemia Secondary to Vascular Malformations
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits